within Pharmacolibrary.Drugs.R_RespiratorySystem.R05D_CoughSuppressantsExclCombinationsWithExpectorants.R05DB13_Butamirate;

model Butamirate
  extends Pharmacolibrary.Drugs.ATC.R.R05DB13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R05DB13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Butamirate is a centrally acting non-opioid antitussive (cough suppressant) that is commonly used in some European and other countries for the symptomatic relief of dry (non-productive) cough. It is not approved in the United States by the FDA, but remains available and used in many countries for OTC or prescription use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are generally not reported in clinical studies or literature. Parameters below are estimated based on pharmacokinetic class similarity to other central antitussive agents and indirect data from drug literature on healthy adults.</p><h4>References</h4><ol><li><p>Płusa, T (2017). [Butamirate citrate in control of cough in respiratory tract inflammation]. <i>Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego</i> 43(254) 69–74. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28875973/\">https://pubmed.ncbi.nlm.nih.gov/28875973</a></p></li><li><p>Bohner, H, et al., &amp; Schütz, H (1997). Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 35(3) 117–122. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9089001/\">https://pubmed.ncbi.nlm.nih.gov/9089001</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Butamirate;
